A Phase 1/2 interventional study of Base-edited hematopoietic stem and progenitor cells and Busulfan in X-linked Severe Combined Immunodeficiency, X-SCID and XSCID, sponsored by National Institute of Allergy and Infectious Diseases (NIAID). Enrolling by invitation at 1 site in United States. Open to male participants aged 3 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by National Institute of Allergy and Infectious Diseases (NIAID) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in X-Linked Combined Immunodeficiency Diseases with a site in United States — 5 open to participants now, 7 under way, none of them phase 3. X-Linked Combined Immunodeficiency Diseases · United States.
Among the 20 studies in X-Linked Combined Immunodeficiency Diseases with a site in United States, this one is the 4th largest by planned enrollment of the 11 interventional ones that give a count, is the only one that started in 2025, is one of 8 in phase 1/2, and was the 20th registered.
28 studies on the registry are indexed under X-Linked Combined Immunodeficiency Diseases; 9 are open to participants now.
Browse X-Linked Combined Immunodeficiency Diseases studies →5 of the 20 studies in X-Linked Combined Immunodeficiency Diseases with a site in United States are open now. Recruiting first, the newest first:
David Williams · Sites in United States
Ages 0–5 · Men only
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 2–50 · Men only
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Healthy volunteers
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States, Canada
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 6 X-Linked Combined Immunodeficiency Diseases studies recruiting now, 2 set no upper age limit and 4 stop at 75 or younger; 6 take children under 18; 1 takes healthy volunteers.
This study: 3 Years to 99 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 8
First in 1997; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 18 is above the median of 9 across 16 interventional studies indexed under X-Linked Combined Immunodeficiency Diseases.
Median enrollment 12 across the 11 interventional studies, 478 across the 8 observational. Of the 8 that completed or were terminated, 3 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 20 have an industry lead sponsor. The 10 most frequent:
National Institute of Allergy and Infectious Diseases (NIAID) is the lead sponsor of 2,449 studies on the registry; 181 are open to participants now.
Of its 406 completed or terminated interventional studies of FDA-regulated products, 303 (75%) have results posted.
National Institute of Allergy and Infectious Diseases (NIAID) has 8 studies filed under X-Linked Combined Immunodeficiency Diseases — fewer than ten, so there is no comparison to draw.
1 of the studies in X-Linked Combined Immunodeficiency Diseases with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03655223RTI InternationalEarly Check: Expanded Screening in Newborns | 2026-11-30 |
Add it to your calendar (.ics) → With an account.
Among the 20 studies in X-Linked Combined Immunodeficiency Diseases with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Background:
X-linked severe combined immunodeficiency (XSCID) is a rare inherited disorder that affects the immune system. It is caused by a change in the IL2RG gene. Researchers are investigating a new type of gene therapy for people with XSCID. This technique, called base-edited stem cell transplants, involves collecting a person s own stem cells, editing the genes to repair IL2RG gene, and returning the edited cells to the person.
Objective:
To test base-edited stem cell transplants in people with XSCID.
Eligibility:
People aged 3 years and older with XSCID.
Design:
Participants will be screened. They will have a physical exam. They may give blood, urine, and stool samples. They may have tests of their heart and lung function. They may have fluid and cells drawn from their bone marrow.
Participants will undergo apheresis. Blood will be taken from the body through a needle inserted into 1 arm. The blood will pass through a machine that separates out the stem cells. The remaining blood will be returned to the body through a different needle. The collected stem cells will undergo gene editing.
Participants will be admitted to the hospital before treatment. They will receive a central line: A flexible tube will be inserted into a large vein. This tube will be used to administer drugs and draw blood during their stay. Before receiving the gene edited cells, participants will receive a reduced dose of busulfan, a drug that makes room in the bone marrow for the treated cells. The busulfan dose may be further adjusted for participants with significant organ damage. Alemtuzumab (Campath) may also be given to some participants to address certain immune problems involving donor T cells from a previous transplant.
The base-edited stem cells will be infused through the central line. Participants will remain in the hospital for at least 3 weeks while they recover.
Follow-up visits will continue for 15 years.
...
Study Description:
This is a phase 1/2, non-randomized study of a single infusion of autologous hematopoietic stem/progenitor cells base-edited to repair interleukin 2 receptor gamma (IL2RG) mutations (BE-HSPC IL2RG) in 18 participants with X-linked severe combined immunodeficiency (X-SCID).
Primary Objective:
Evaluate the safety of treatment with BE-HSPC IL2RG in participants with X-SCID.
Secondary Objectives:
Evaluate efficacy of treatment with BE-HSPC IL2RG in participants with X-SCID.
Exploratory Objectives:
Primary Endpoint:
Safety of treatment with BE-HSPC IL2RG, by quantifying frequency and severity of adverse events (AEs) related to study agent from infusion to 12 months after infusion.
Secondary Endpoints (24 months post-study agent infusion):
Immune reconstitution:
Exploratory Endpoints:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
In order to be eligible to participate in this study, an individual must meet all of the following criteria:
Acceptable forms of contraception are:
--For males: Condoms or other contraception with partner.
OR
demonstrated requirement for intravenous gamma globulin (IVIG) (significant drop over 3 to 6 weeks between peak and trough IgG levels).
-Must be willing to have blood and tissue samples stored IN ADDITION, patients must satisfy the following Laboratory Criteria AND Clinical Criteria
Laboratory Criteria: (>=1 must be present)
Clinical Criteria: (>=1 must be present)
I. Infections (not including molluscum, warts or mucocutaneous candidiasis; see VII and VIII below):
Three significant new or chronic active infections during the 2 years preceding evaluation for enrollment, with each infection accounting for one criterion.
Infections are defined as an objective sign of infection
In addition to one or more of these signs/symptoms of possible infection, there also must be at least 1 of the following criteria as evidence of the attending physician s intent to treat a significant infection (a. and b.) or objective evidence for a specific pathogen causing the infection (c.)
Treatment (not prophylaxis) with systemic antibacterial, antifungal or antiviral antibiotics >=14 days
OR
Hospitalization of any duration for infection
OR
II. Chronic pulmonary disease as defined by:
Bronchiectasis by x-ray computerized tomography
OR
Pulmonary function test (PFT) evidence for restrictive or obstructive disease that is 60% of Predicted for Age
OR
III. Gastrointestinal enteropathy:
Diarrhea-watery stools >=3 times per day (of at least 3 months duration that is not a result of infection as defined in criterion I. above)
OR
Endoscopic evidence (gross and histologic) for enteropathy (endoscopy will only be performed if medically indicated)
OR
IV. Poor nutrition: Requires G-tube or intravenous feeding supplement to maintain weight or nutrition.
V. Auto- or allo-immunity: Examples must include objective physical findings that include, but are not limited to any one of alopecia, severe rashes at more than one anatomic site and not due to infection, uveitis, joint pain with redness or swelling or limitation of movement that is not a result of infection, lupus-like lesions, and granulomas (Does not include auto- or allo-immune enteropathy which is criterion iii). Where possible and appropriate, diagnosis will be supported by histopathology or other diagnostic modality.
VI. Failure to grow in height: \<=3rd percentile for age
VII. Skin molluscum contagiosum OR warts (this criterion is satisfied if molluscum consists of >=10 lesions or there are two or more lesions at each of two or more widely separated anatomic sites; or there are >=3 warts at different anatomic sites at the same time; or the patient has both molluscum and warts)
VIII. Mucocutaneous candidiasis (chronic oral thrush or candida esophagitis or candida intertriginous infection or candida nail infections; must be culture positive to satisfy this criterion)
IX. Hypogammaglobulinemia: requires regular IgG supplementation
Criteria for eligibility for Campath:
Evidence of organ disease attributable to T cell dysregulation (e.g., elevated transaminases)
EXCLUSION CRITERIA:
An individual who meets any of the following criteria will be excluded from participation in this study:
NOTE: Alemtuzumab (Campath) is no longer distributed commercially. To receive product, the physician must contact the program for the participant. If Campath use is indicated and the participant is not willing to consent to submit their info (demographics, contact information, and rationale for use) to the program such that we can obtain the drug, then the participant will not undergo gene therapy and will be withdrawn.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: Base-edited hematopoietic stem and progenitor cells · Drug: Busulfan · Drug: Palifermin · Drug: Filgrastim · Drug: Plerixafor · Drug: Campath
Investigational/Study Agent: Base-edited autologous CD34 plus hematopoietic stem and progenitor cell product. A one-time dose \>5(SqrRoot) 10\^6 base-edited cells/kg body weight will be administered to each participant. The exact dosage depends on the number of viable cells that are repaired, cryopreserved, and thawed. The study agent will be administered by IV infusion in a volume of approximately 50 mL over about 15-30 minutes, in accordance with NIH CC DTM infusion policy.
Transplant Conditioning Agent: An alkylating chemotherapy drug to enhance engraftment of the study agent (base-edited stem cells). For this study, busulfan is administered once daily (3 mg/kg) x 2 days, targeting a daily busulfan AUC of 4500-6500 micromol\*min/L or a cumulative AUC of 9000 micromol\*min/L (for the 2 days of therapy if levels are available. Busulfan will be infused over 3 hours each day as per standard clinical practice.
Mucositis prophylaxis: As is standard practice prior to busulfan conditioning, IV infusion of keratinocyte growth factor (palifermin) will be administered at 60 micrograms/kg/day for 3 days before initiation of busulfan (days -6 to -4), as well as for the 3 days following study agent administration (days 1 to 3).
Stem Cell Mobilizing Agent: Subcutaneous administration for 6 consecutive days. It is necessary to mobilize stem cells for collection.
Stem Cell Mobilizing Agent: Subcutaneous administration for 2 consecutive days to improve stem cell collection.
Immunomodulating Agent: May be administered subcutaneously Days -21 through Day -19 in patients who demonstrate evidence of donor T cell dysregulation
Quantify frequency and severity of adverse events (AEs) related to study agent from infusion to 12 months after infusion.
Evaluate the safety of treatment with BE-HSPC IL2RG in participants with X-SCID.
Time frame: 12 months
Evaluate percentage of participants with >= 5% mutation-repaired alleles in PBMCs.
Measure efficacy of treatment by assessing efficiency of base editor at repair of mutations.
Time frame: 24 months
Evaluate editing efficiency in peripheral blood cells (such as T, B, and natural killer [NK] cells).
Measure efficacy of treatment by assessing molecular evidence for mutation repair.
Time frame: 24 months
Evaluate Immune reconstitution: a. T, B, and NK cell number improvement from baseline. b. Emergence of naive T cells and CD31+ recent thymic emigrants.c. B-cell function: immunoglobulin (Ig) production. d. Specific responses to vacci...
Measure efficacy of treatment by assessing immune reconstitution as indicated by 1) increase in immune cell numbers; 2) restoration of thymic function with production of na(SqrRoot) ve T cells and CD31+ T cells; 3) Evaluate restoration of B-cell function.
Time frame: 24 months
Evaluate clinical efficacy by improvement from baseline problems such as recurrent infection, chronic norovirus, protein-losing enteropathy, gastrointestinal complaints, growth failure, malnutrition, or immune dysregulation.
Measure efficacy of treatment by assessing comparison of clinical status before and after treatment as indicator of response to improved immune function.
Time frame: 24 months
Evaluate frequency and severity of all study agent-related AEs and serious adverse events (SAEs) from time of study product infusion.
Measure efficacy of treatment by assessing intervention-related AE rate.
Time frame: 24 months
Plan to share: Undecided
Started May 2025 (actual). Primary completion is estimated for Dec 2034, 115 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Busulfan · Fibroblast Growth Factor 7 · Filgrastim · Plerixafor · Alemtuzumab
X-Linked Combined Immunodeficiency Diseases →
National Institute of Allergy and Infectious Diseases (NIAID) →